EP
TEVA icon

Essential Partners’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Essential Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.27K Hold
32
– – ﹤0.01% 2098
2026
Q2 		$1.08K Hold
32
– – ﹤0.01% 2210
2026
Q1 		$964 Hold
32
– – ﹤0.01% 2259
2025
Q4 		$999 Sell
32
-77
-71% -$1.9K ﹤0.01% 2031
2025
Q3 		$2.2K Buy
+109
New +$1.91K ﹤0.01% 1765

Other funds holding TEVA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
CA
Continental Advisors Park City, Utah $233M AUM 14.5% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
GIA
GHP Investment Advisors Denver, Colorado $2.68B AUM 19.3% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
ASR Vermogensbeheer
ASR Vermogensbeheer Utrecht, Netherlands $10.1B AUM 30.4% 1-Year Est. Return
RWA
Redhawk Wealth Advisors Minneapolis, Minnesota $987M AUM 25.25% 1-Year Est. Return

Essential Partners's TEVA Position: Q3 2026 in Review

Essential Partners held its Teva Pharmaceutical Industries Limited (TEVA) position steady in Q3 2026 at 32 shares worth $1.27K. The position accounts for ﹤0.01% of the portfolio, ranked #2098.

Essential Partners first reported a position in TEVA in Q3 2025 and has held it in 5 quarters since. The position peaked at $2.2K in Q3 2025. 44 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

  • Essential Partners held 32 shares of Teva Pharmaceutical Industries Limited worth $1.27K as of Q3 2026.
  • Essential Partners left its Teva Pharmaceutical Industries Limited share count unchanged in Q3 2026.
  • Teva Pharmaceutical Industries Limited made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2098 holding.
  • Essential Partners first reported a position in Teva Pharmaceutical Industries Limited in Q3 2025 and has held it in 5 quarters since.
  • Essential Partners's Teva Pharmaceutical Industries Limited position peaked at $2.2K in Q3 2025.
  • 44 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.